Markets

Prosensa prices IPO at $13, the high end of the range

Prosensa, a late-stage biotech developing treatments for Duchenne muscular dystrophy, raised $78 million by offering 6.0 million shares at $13, the high end of the range of $11 to $13. Prosensa plans to list on the NASDAQ under the symbol RNA. Prosensa initially filed confidentially on 4/16/2013. J.P. Morgan and Citi were the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos